Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9NIR

Human Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) inhibitor complex

これはPDB形式変換不可エントリーです。
9NIR の概要
エントリーDOI10.2210/pdb9nir/pdb
分子名称Ectonucleotide pyrophosphatase/phosphodiesterase family member 3, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (9 entities in total)
機能のキーワードec 3.6.1.9, hydrolase
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数1
化学式量合計99555.42
構造登録者
Fernandez, D.,Li, L.,Carozza, J.A. (登録日: 2025-02-26, 公開日: 2026-01-07)
主引用文献Wang, S.,Johnson, R.M.,Carozza, J.A.,Fernandez, D.,Scicinski, J.,Verity, N.A.,Mardjuki, R.,Cao, X.,Guo, Y.,Papkoff, J.,Ray, N.,Li, L.
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.
Cell Rep Med, 6:102336-102336, 2025
Cited by
PubMed Abstract: Only one in five patients respond to immune checkpoint inhibitors, which primarily target adaptive immunity. Ectonucleotide pyrophosphatase/phophodiesterase 1 (ENPP1), the dominant hydrolase of 2'3'-cyclic-GMP-AMP (cGAMP) that suppresses downstream stimulator of interferon genes (STING) signaling, has emerged as a promising innate immunotherapy target. However, existing ENPP1 inhibitors have been optimized for prolonged systemic residence time rather than effective target inhibition within tumors. Here, we report the characterization of STF-1623, a highly potent ENPP1 inhibitor with an exceptionally long tumor residence time despite rapid systemic clearance, enabled by its high ENPP1 binding affinity and slow dissociation rate. We show that membrane-bound ENPP1 on tumor cells, not the abundant soluble ENPP1 in serum, drives tumor progression. Consequently, STF-1623 unleashes anti-tumor immunity to produce robust anti-tumor and anti-metastatic effects across multiple tumor models. Conceptually, this work establishes a noncovalent small-molecule inhibitor of ENPP1 with ultralong drug-target engagement as a safe and precise strategy to activate STING within tumors.
PubMed: 40914167
DOI: 10.1016/j.xcrm.2025.102336
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.7 Å)
構造検証レポート
Validation report summary of 9nir
検証レポート(詳細版)ダウンロードをダウンロード

250359

件を2026-03-11に公開中

PDB statisticsPDBj update infoContact PDBjnumon